SD BIOSENSOR announced on the 13th that its sales revenue for the first half of this year increased by 2.3% compared to the same period last year, reaching 351.8 billion won, while its operating loss grew by 38.1% to 35.1 billion won.
The company generated a net profit of 256.3 billion won in the first half of this year due to corporate tax refunds, in contrast to a net loss of 29.2 billion won recorded in the first half of last year.
The company stated that sales of all product categories increased evenly in the first half of this year, noting that the proportion of non-COVID product sales rose to 97% of the total, an 8 percentage point increase compared to the same period last year. Representative products include blood glucose diagnostic products, sexually transmitted disease diagnostic products including simultaneous HIV and syphilis diagnostic kits, and malaria diagnostic kits for vector-borne infections.
Regarding the operating loss, the company explained, 'This is due to the amortization of intangible assets that occurred during the consolidation accounting process of its U.S. subsidiary Meridian Bioscience,' adding, 'This is an accounting expense with no cash outflow.'